Keywords: dabigatran, bleeding, idarucizumab, reversal (PubMed Search)
Posted: 7/6/2015 by Bryan Hayes, PharmD
Click here to contact Bryan Hayes, PharmD
The New England Journal of Medicine and Lancet both published studies evaluating idarucizumab for reversal of dabigatran. It is a monoclonal antibody fragment that binds dabigatran with high affinity. Dr. Ryan Radecki summarizes the two articles on his EM Lit of Note blog.
Here are a few take home points from these early studies:
Pollack CV, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015 Jun 22. [Epub ahead of print, PMID 26095746]
Glund S, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in health male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015 Jun 15. [Epub ahead of print, PMID 26088268]
Follow me on Twitter (@PharmERToxGuy) or Google Plus (+bryanhayes13)
Download the UMEM Pearls App!
Subscribe to daily UMEM Pearls (FREE!) via: